312 related articles for article (PubMed ID: 12731493)
1. Recruiting human subjects without IRB review/approval.
Maloney DM
Hum Res Rep; 2002 Aug; 17(8):3. PubMed ID: 12731493
[No Abstract] [Full Text] [Related]
2. Continued concern: human subject protection, the institutional review board, and continuing review.
Hoffman S
Tenn Law Rev; 2001; 68(4):725-70. PubMed ID: 16189912
[No Abstract] [Full Text] [Related]
3. Time for new rules on human subjects research?
Dresser R
Hastings Cent Rep; 1998; 28(6):23-4. PubMed ID: 9868606
[No Abstract] [Full Text] [Related]
4. Protecting research subjects--what must be done.
Shalala D
N Engl J Med; 2000 Sep; 343(11):808-10. PubMed ID: 10984573
[No Abstract] [Full Text] [Related]
5. Research involving children: regulations, review boards and reform.
Gandhi R
J Health Care Law Policy; 2005; 8(2):264-330. PubMed ID: 16471026
[No Abstract] [Full Text] [Related]
6. Reporting problems in human research and resultant investigations by IRBs.
Maloney DM
Hum Res Rep; 2002 Aug; 17(8):6-7. PubMed ID: 12731495
[No Abstract] [Full Text] [Related]
7. Improving protection for research subjects.
Steinbrook R
N Engl J Med; 2002 May; 346(18):1425-30. PubMed ID: 11986426
[No Abstract] [Full Text] [Related]
8. New federal guidance adds duties for institutional review boards (IRBs).
Maloney DM
Hum Res Rep; 2005 Nov; 20(11):1-2. PubMed ID: 16358479
[No Abstract] [Full Text] [Related]
9. Clinical trials face heightened scrutiny as science and commerce appear to merge.
Lorman AJ
J Biolaw Bus; 2001; 4(4):23-32. PubMed ID: 12751494
[TBL] [Abstract][Full Text] [Related]
10. Institutional review boards and the privacy of human research subjects.
Maloney DM
Hum Res Rep; 2002 Aug; 17(8):1-2. PubMed ID: 12731492
[No Abstract] [Full Text] [Related]
11. Biotech and pharma face more costly clinical trials.
Brower V
Nat Biotechnol; 1998 Aug; 16(8):714. PubMed ID: 9702762
[No Abstract] [Full Text] [Related]
12. The impact of escalating regulatory requirements on the conduct of clinical research.
Gordon BG; Kessinger A; Mann SL; Prentice ED
Cytotherapy; 2003; 5(4):309-13. PubMed ID: 12944237
[TBL] [Abstract][Full Text] [Related]
13. New privacy rule has more tasks for IRBs.
Maloney DM
Hum Res Rep; 2001 Feb; 16(2):4. PubMed ID: 12530379
[No Abstract] [Full Text] [Related]
14. How institutional review boards (IRBs) can handle adverse event reports.
Maloney DM
Hum Res Rep; 2006 Jan; 21(1):1-3. PubMed ID: 16789305
[No Abstract] [Full Text] [Related]
15. IRBs, human subjects, and reporting adverse events.
Maloney DM
Hum Res Rep; 2005 Nov; 20(11):3. PubMed ID: 16358480
[No Abstract] [Full Text] [Related]
16. Institutional review board (IRB) violated numerous regulations.
Maloney DM
Hum Res Rep; 2001 Feb; 16(2):7-8. PubMed ID: 12530381
[No Abstract] [Full Text] [Related]
17. IRBs, data sharing, and privacy of human subjects.
Maloney DM
Hum Res Rep; 2002 Apr; 17(4):3. PubMed ID: 12374179
[No Abstract] [Full Text] [Related]
18. Research infrastructure and IRB/FDA requirements.
Cohen J
Med Health R I; 2000 Dec; 83(12):382-5. PubMed ID: 11190124
[No Abstract] [Full Text] [Related]
19. IRB triage of projects that involve medical record review.
Amdur R; Speers MA; Bankert E
IRB; 2000 Jan; 22(1):4-7. PubMed ID: 12546009
[No Abstract] [Full Text] [Related]
20. HIPAA and what institutional review boards (IRBs) do not have to review.
Maloney DM
Hum Res Rep; 2003 Dec; 18(12):1-2. PubMed ID: 15027429
[No Abstract] [Full Text] [Related]
[Next] [New Search]
